Management of mucosal melanomas of the head and neck: Did we make any progress?

Current Opinion in Otolaryngology and Head and Neck Surgery

Volumn 18, Issue 2, 2010, Pages 101-106

  Moreno, Mauricio A ^a   Hanna, Ehab Y ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Biochemotherapy; Mucosal melanoma; Outcomes; Radiotherapy; Surgery

Indexed keywords

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; HEAD AND NECK CANCER; HUMAN; MELANOMA; MOUTH CANCER; NECK DISSECTION; NOSE CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW;

COMBINED MODALITY THERAPY; DISEASE PROGRESSION; HUMANS; MELANOMA; NASAL MUCOSA; NEOPLASM STAGING; PARANASAL SINUS NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS;

EID: 77949581469     PISSN: 10689508     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOO.0b013e3283374d31     Document Type: Review

References (50)

1. Manolidis S, Donald PJ. Malignant mucosal melanoma of the head and neck: review of the literature and report of 14 patients. Cancer 1997; 80:1373-1386.
2. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998; 83:1664-1678.
3. Batsakis JG, Regezi JA, Solomon AR, et al. The pathology of head and neck tumors: mucosal melanomas, part 13. Head Neck Surg 1982; 4:404-418.
4. McLean N, Tighiouart M, Muller S. Primary mucosal melanoma of the head and neck. Comparison of clinical presentation and histopathologic features of oral and sinonasal melanoma. Oral Oncol 2008; 44:1039-1046.
5. Prasad ML, Busam KJ, Patel SG, et al. Clinicopathologic differences in malignant melanoma arising in oral squamous and sinonasal respiratory mucosa of the upper aerodigestive tract. Arch Pathol Lab Med 2003; 127:997-1002.
6. Ballantyne AJ. Malignant melanoma of the skin of the head and neck. An analysis of 405 cases. Am J Surg 1970; 120:425-431.
7. Prasad ML, Patel SG, Huvos AG, et al. Primary mucosal melanoma of the head and neck: a proposal for microstaging localized, stage I (lymph node-negative) tumors. Cancer 2004; 100:1657-1664.
8. Thompson LD, Wieneke JA, Miettinen M. Sinonasal tract and nasopharyngeal melanomas: a clinicopathologic study of 115 cases with a proposed staging system. Am J Surg Pathol 2003; 27:594-611.
9. Moreno MA, Roberts DB, Kupferman ME, et al. Mucosal melanoma of the nose and paranasal sinuses, a contemporary experience from M.D. Anderson Cancer Center. Cancer (in press).
10. Greene F. AJCC cancer staging manual. New York, USA: Springer; 2002.
11. Goerres GW, Stoeckli SJ, von Schulthess GK, et al. FDG PET for mucosal malignant melanoma of the head and neck. Laryngoscope 2002; 112:381-385.
12. Kostakoglu L, Wong JC, Barrington SF, et al. Speech-related visualization of laryngeal muscles with fluorine-18-FDG. J Nucl Med 1996; 37:1771-1773.
13. Mendenhall WM, Amdur RJ, Hinerman RW, et al. Head and neck mucosal melanoma. Am J Clin Oncol 2005; 28:626-630.
14. Wagner M, Morris CG, Werning JW, et al. Mucosal melanoma of the head and neck. Am J Clin Oncol 2008; 31:43-48.
15. Medina JE, Ferlito A, Pellitteri PK, et al. Current management of mucosal melanoma of the head and neck. J Surg Oncol 2003; 83:116-122.
16. Bachar G, Loh KS, O'Sullivan B, et al. Mucosal melanomas of the head and neck: experience of the Princess Margaret Hospital. Head Neck 2008; 30:1325-1331.
17. Penel N, Mallet Y, Mirabel X, et al. Primary mucosal melanoma of head and neck: prognostic value of clear margins. Laryngoscope 2006; 116:993-995.
18. Lee SP, Shimizu KT, Tran LM, et al. Mucosal melanoma of the head and neck: the impact of local control on survival. Laryngoscope 1994; 104:121-126.
19. Nicolai P, Battaglia P, Bignami M, et al. Endoscopic surgery for malignant tumors of the sinonasal tract and adjacent skull base: a 10-year experience. Am J Rhinol 2008; 22:308-316.
20. Patel SG, Prasad ML, Escrig M, et al. Primary mucosal malignant melanoma of the head and neck. Head Neck 2002; 24:247-257.
21. Krengli M, Masini L, Kaanders JH, et al. Radiotherapy in the treatment of mucosal melanoma of the upper aerodigestive tract: analysis of 74 cases. A Rare Cancer Network study. Int J Radiat Oncol Biol Phys 2006; 65:751-759.
22. Starek I, Koranda P, Benes P. Sentinel lymph node biopsy: a new perspective in head and neck mucosal melanoma? Melanoma Res 2006; 16:423-427.
23. Baptista P, Garcia Velloso MJ, Salvinelli F, et al. Radioguided surgical strategy in mucosal melanoma of the nasal cavity. Clin Nucl Med 2008; 33:14-18.
24. Abramova L, Parekh J, Irvin WP Jr, et al. Sentinel node biopsy in vulvar and vaginal melanoma: presentation of six cases and a literature review. Ann Surg Oncol 2002; 9:840-846.
25. Sugiyama VE, Chan JK, Kapp DS. Management of melanomas of the female genital tract. Curr Opin Oncol 2008; 20:565-569.
26. Temam S, Mamelle G, Marandas P, et al. Postoperative radiotherapy for primary mucosal melanoma of the head and neck. Cancer 2005; 103:313-319.
27. Owens JM, Roberts DB, Myers JN. The role of postoperative adjuvant radiation therapy in the treatment of mucosal melanomas of the head and neck region. Arch Otolaryngol Head Neck Surg 2003; 129:864-868.
28. Nandapalan V, Roland NJ, Helliwell TR, et al. Mucosal melanoma of the head and neck. Clin Otolaryngol Allied Sci 1998; 23:107-116.
29. Suit HD. Local control and patient survival. Int J Radiat Oncol Biol Phys 1992; 23:653-660.
30. Krengli M, Jereczek-Fossa BA, Kaanders JH, et al. What is the role of radiotherapy in the treatment of mucosal melanoma of the head and neck? Crit Rev Oncol Hematol 2008; 65:121-128.
31. Chang DT, Amdur RJ, Morris CG, et al. Adjuvant radiotherapy for cutaneous melanoma: comparing hypofractionation to conventional fractionation. Int J Radiat Oncol Biol Phys 2006; 66:1051-1055.
32. Yanagi T, Mizoe JE, Hasegawa A, et al. Mucosal malignant melanoma of the head and neck treated by carbon ion radiotherapy. Int J Radiat Oncol Biol Phys 2009; 74:15-20.
33. Gilligan D, Slevin NJ. Radical radiotherapy for 28 cases of mucosal melanoma in the nasal cavity and sinuses. Br J Radiol 1991; 64:1147-1150.
34. Shibuya H, Takeda M, Matsumoto S, et al. The efficacy of radiation therapy for a malignant melanoma in the mucosa of the upper jaw: an analytic study. Int J Radiat Oncol Biol Phys 1993; 25:35-39.
35. Wada H, Nemoto K, Ogawa Y, et al. A multiinstitutional retrospective analysis of external radiotherapy for mucosal melanoma of the head and neck in Northern Japan. Int J Radiat Oncol Biol Phys 2004; 59:495-500.
36. Tsunemoto H, Morita S, Mori S. Characteristics of malignant melanoma cells in the treatment with fast neutrons. Pigment Cell Res 1989; 2:372-378.
37. Eton O, Legha SS, Bedikian AY, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002; 20:2045-2052.
38. O'Day SJ, Gammon G, Boasberg PD, et al. Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma. J Clin Onc ol 1999; 17:2752-2761.
39. Keilholz U, Conradt C, Legha SS, et al. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol 1998; 16:2921-2929.
40. Bartell HL, Bedikian AY, Papadopoulos NE, et al. Biochemotherapy in patients with advanced head and neck mucosal melanoma. Head Neck 2008; 30:1592-1598.
41. Ives NJ, Stowe RL, Lorigan P, et al. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 2007; 25:5426-5434.
42. Atkins MB, Hsu J, Lee S, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2008; 26:5748-5754.
43. Bajetta E, Del Vecchio M, Nova P, et al. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. Ann Oncol 2006; 17:571-577.
44. Bedikian AY, Johnson MM, Warneke CL, et al. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest 2008; 26:624-633.
45. Cuevas E, Jones DB, Wright DH. Immunohistochemical detection of tumour growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues. J Pathol 1993; 169:477-478.
46. Kim DK, Kim DW, Kim SW, et al. Ki67 antigen as a predictive factor for prognosis of sinonasal mucosal melanoma. Clin Exp Otorhinolaryngol 2008; 1:206-210.
47. Piras F, Murtas D, Minerba L, et al. Nuclear survivin is associated with disease recurrence and poor survival in patients with cutaneous malignant melanoma. Histopathology 2007; 50:835-842.
48. Chen N,Gong J, Chen X, et al. Caspases and inhibitor of apoptosis proteins in cutaneous and mucosal melanoma: expression profile and clinicopathologic significance. Hum Pathol 2009; 40:950-956.
49. Garrido MC, Bastian BC. KIT as a therapeutic target in melanoma. J Invest Dermatol 2010; 130:20-27.
50. Rivera RS, Nagatsuka H, Gunduz M, et al. C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma. Virchows Arch 2008; 452:27-32.